IL290045A - Deuterium-converted mk2 pathway inhibitors and methods of using them - Google Patents

Deuterium-converted mk2 pathway inhibitors and methods of using them

Info

Publication number
IL290045A
IL290045A IL290045A IL29004522A IL290045A IL 290045 A IL290045 A IL 290045A IL 290045 A IL290045 A IL 290045A IL 29004522 A IL29004522 A IL 29004522A IL 290045 A IL290045 A IL 290045A
Authority
IL
Israel
Prior art keywords
deuterated
methods
same
pathway inhibitors
pathway
Prior art date
Application number
IL290045A
Other languages
English (en)
Hebrew (he)
Original Assignee
Aclaris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aclaris Therapeutics Inc filed Critical Aclaris Therapeutics Inc
Publication of IL290045A publication Critical patent/IL290045A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL290045A 2019-07-31 2022-01-23 Deuterium-converted mk2 pathway inhibitors and methods of using them IL290045A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962881026P 2019-07-31 2019-07-31
PCT/US2020/044558 WO2021022186A1 (en) 2019-07-31 2020-07-31 Deuterated mk2 pathway inhibitors and methods of using the same

Publications (1)

Publication Number Publication Date
IL290045A true IL290045A (en) 2022-03-01

Family

ID=74228512

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290045A IL290045A (en) 2019-07-31 2022-01-23 Deuterium-converted mk2 pathway inhibitors and methods of using them

Country Status (11)

Country Link
US (1) US20220288070A1 (ko)
EP (1) EP4003344A4 (ko)
JP (1) JP2022542434A (ko)
KR (1) KR20220041180A (ko)
CN (1) CN114206339A (ko)
AU (1) AU2020319879A1 (ko)
BR (1) BR112022001324A2 (ko)
CA (1) CA3149304A1 (ko)
IL (1) IL290045A (ko)
MX (1) MX2022001151A (ko)
WO (1) WO2021022186A1 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3172088A1 (en) * 2020-03-27 2021-09-30 Walter Smith Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
CR20230468A (es) 2021-03-31 2023-12-07 Xinthera Inc Inhibidores de mk2 y usos de estos
TW202317544A (zh) 2021-07-09 2023-05-01 美商辛瑟拉股份有限公司 吡啶酮mk2抑制劑及其用途
WO2023001282A1 (zh) * 2021-07-23 2023-01-26 南京明德新药研发有限公司 杂环取代的嘧啶衍生物
WO2023125707A1 (zh) * 2021-12-29 2023-07-06 上海美悦生物科技发展有限公司 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
WO2023134765A1 (zh) * 2022-01-14 2023-07-20 上海翰森生物医药科技有限公司 含五元环类衍生物、其制备方法和应用
CN118525005A (zh) 2022-01-14 2024-08-20 上海翰森生物医药科技有限公司 含吡啶多环类衍生物、其制备方法和应用
US20230286950A1 (en) * 2022-02-04 2023-09-14 Aclaris Therapeutics, Inc. Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds
WO2023165554A1 (zh) * 2022-03-03 2023-09-07 深圳信立泰药业股份有限公司 一种氘代三联吡啶二酮化合物或其盐及其制备方法与应用
WO2024150014A1 (en) 2023-01-13 2024-07-18 Poolbeg Pharma (UK) Limited Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome
CN118344289A (zh) * 2023-01-13 2024-07-16 上海美悦生物科技发展有限公司 苯基取代的杂芳基类化合物及其药物组合物、制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010136474A2 (en) * 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
JP5848775B2 (ja) * 2010-12-06 2016-01-27 コンフルエンス・ライフ・サイエンシズ，インコーポレーテッド 置換ピリジノンピリジニル化合物
US9359300B2 (en) * 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
LT3003039T (lt) * 2013-06-07 2021-05-10 Aclaris Therapeutics, Inc. Metil/fluor-piridinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai ir fluor-pirimidinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai
WO2017180589A1 (en) * 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
TWI828644B (zh) * 2017-12-06 2024-01-11 仁新醫藥股份有限公司 微管蛋白抑制劑

Also Published As

Publication number Publication date
AU2020319879A1 (en) 2022-02-03
JP2022542434A (ja) 2022-10-03
CA3149304A1 (en) 2021-02-04
KR20220041180A (ko) 2022-03-31
EP4003344A4 (en) 2023-07-26
BR112022001324A2 (pt) 2022-03-22
MX2022001151A (es) 2022-02-22
CN114206339A (zh) 2022-03-18
EP4003344A1 (en) 2022-06-01
US20220288070A1 (en) 2022-09-15
WO2021022186A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
IL290045A (en) Deuterium-converted mk2 pathway inhibitors and methods of using them
IL290399A (en) kras g12c inhibitors and methods of using them
IL272512A (en) KRAS G12C inhibitors and methods of using them
IL288381A (en) Tead inhibitors and their uses
IL288384A (en) Tead inhibitors and their uses
EP3596085A4 (en) DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
IL283592A (en) Apol1 inhibitors and methods of using them
IL287751A (en) kcnt1 inhibitors and methods of use
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL307187A (en) MK2 inhibitors and their uses
IL287768A (en) kcnt1 inhibitors and methods of use
IL287973A (en) acss2 inhibitors and methods of their use
EP3572400C0 (en) EZH2 INHIBITOR AND ITS USE
SG11202104010PA (en) Rgmc-selective inhibitors and use thereof
IL274504A (en) 2ACSS inhibitors and methods of their use
IL286485A (en) pi4-kinase inhibitors and methods of using them
IL279276A (en) ERK inhibitor and use thereof
SG10201913562VA (en) Hsp90 inhibitor oral formulations and related methods
IL286149A (en) Caspase inhibitors and methods of using them
EP3793552C0 (en) ABHD12 INHIBITORS AND METHODS OF MANUFACTURE AND USE THEREOF
EP3792257C0 (en) DEUTERED DEFACTINIB COMPOUND AND ITS USES
IL289127A (en) ppm1a inhibitors and methods of using them
EP3968994C0 (en) ABHD12 INHIBITORS AND METHODS FOR THE PRODUCTION AND USE THEREOF
GB201908884D0 (en) Inhibitors and use
IL281865A (en) Instruments and methods for income and use